Takeda Pharmaceuticals has entered into an alliance with Sanford-Burnham Research Institute and Florida Hospital in Florida, US.
A two-year deal has been confirmed between the Japanese pharmaceutical major and the non-profit biomedical research facility and its joint venture with Florida Hospital, the Translational Research Institute for Metabolism and Diabetes.
The collaboration includes funding of research, and Sanford-Burnham officials have said that this is one of the most ambitious research partnerships that Takeda has agreed with the not-for-profit sector, although financial terms of the agreement have not been disclosed.
Takeda has previously made large investments for research intro diabetes and obesity treatments, contrasting other pharmaceutical companies that have slashed their obesity research funding in recent years.
The move follows Takeda’s acquisition of a new obesity medication from Amylin Pharmaceuticals in 2010, while the company is continuing tests on TAK-875, a new class of drug to treat diabetes.
